Displaying drugs 1226 - 1250 of 2269 in total
Activated natural killer cell therapy
Investigational
Efmarodocokin alfa
Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Investigational
Canoctakin
Investigational
Selisistat
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Heptaethylene glycol
Experimental
Ifinatamab deruxtecan
Investigational
Fenvalerate
Investigational
3,6,9,12,15,18-HEXAOXAICOSANE
Experimental
Zilovertamab
Investigational
3,6,9,12,15-Pentaoxaheptadecane
Experimental
5-(2-hydroxyethyl)nonane-1,9-diol
Experimental
PG-530742
PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Investigational
CP-122721
CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Investigational
Enokizumab
A humanized immunoglobulin G1k anti-interleukin-9 mAb.
Investigational
Matched Description: … A humanized immunoglobulin G1k anti-interleukin-9 mAb. …
anti-OX40 antibody BMS 986178
A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.
Investigational
JQ1
First-in-class potent and selective inhibitor of the BRD4 signaling pathway.
Investigational
Matched Iupac: … chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- …
3,6,9,12,15-PENTAOXATRICOSAN-1-OL
Experimental
Mirvetuximab
Investigational
Ziltivekimab
Ziltivekimab is under investigation in clinical trial NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation).
Investigational
Andecaliximab
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
Investigational
Matched Description: … Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). ... clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 …
Rheinanthrone
Rheinanthrone is the active metabolite of senna glycoside DB11365 known for its laxative effect . It is commonly produced by plants of the Rheum species .
Experimental
Matched Iupac: … 4,5-dihydroxy-10-oxo-9,10-dihydroanthracene-2-carboxylic acid …
Displaying drugs 1226 - 1250 of 2269 in total